Literature DB >> 1663792

m-Chlorophenylpiperazine as a probe of serotonin function.

R S Kahn1, S Wetzler.   

Abstract

m-Chlorophenylpiperazine (mCPP) is the most extensively used probe of serotonin function in psychiatry. This article reviews its in vitro and in vivo properties in animals, normal human subjects, and psychiatric patients. mCPP is a safe, reliable, direct 5-hydroxytryptamine (5HT) agonist, which may be used to evaluate 5HT receptor sensitivity. It causes a consistent, dose-dependent elevation of ACTH, cortisol, and prolactin levels in both animals and humans, as well as increased body temperature in man. It also causes a variety of behavioral effects, depending on the population studied. These effects are probably 5HT receptor-related, although specific 5HT receptor subtype mechanisms have not yet been established. mCPP may be considered an important addition to armamentarium of 5HT receptor probes, which is especially useful until more selective 5HT receptor agonists have been tested.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1663792     DOI: 10.1016/0006-3223(91)90184-n

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  32 in total

Review 1.  Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine.

Authors:  S Rotzinger; M Bourin; Y Akimoto; R T Coutts; G B Baker
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 2.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

3.  Relationship of disinhibition and aggression to blunted prolactin response to meta-chlorophenylpiperazine in cocaine-dependent patients.

Authors:  Ashwin A Patkar; Paolo Mannelli; Kathleen Peindl; Kevin P Hill; Raman Gopalakrishnan; Wade H Berrettini
Journal:  Psychopharmacology (Berl)       Date:  2006-01-17       Impact factor: 4.530

4.  The effects of paroxetine and nefazodone on sleep: a placebo controlled trial.

Authors:  A L Sharpley; D J Williamson; M E Attenburrow; G Pearson; P Sargent; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

Review 5.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 6.  The pharmacologic management of insomnia in patients with HIV.

Authors:  Toma S Omonuwa; Harold W Goforth; Xavier Preud'homme; Andrew D Krystal
Journal:  J Clin Sleep Med       Date:  2009-06-15       Impact factor: 4.062

7.  Mono N-aryl ethylenediamine and piperazine derivatives are GABAA receptor blockers: implications for psychiatry.

Authors:  R F Squires; E Saederup
Journal:  Neurochem Res       Date:  1993-07       Impact factor: 3.996

Review 8.  Neurobiology of anorexia and bulimia nervosa.

Authors:  Walter Kaye
Journal:  Physiol Behav       Date:  2007-11-29

9.  Effects of the serotonergic agonist mCPP on male rats in the quinpirole sensitization model of obsessive-compulsive disorder (OCD).

Authors:  Mark C Tucci; Anna Dvorkin-Gheva; Dawn Graham; Sean Amodeo; Paul Cheon; Ashley Kirk; John Peel; Leena Taji; Henry Szechtman
Journal:  Psychopharmacology (Berl)       Date:  2013-01-25       Impact factor: 4.530

10.  Role of 5-HT2C receptors in the enhancement of c-Fos expression induced by a 5-HT2B/2C inverse agonist and 5-HT 2 agonists in the rat basal ganglia.

Authors:  S Navailles; M Lagière; C Le Moine; P De Deurwaerdère
Journal:  Exp Brain Res       Date:  2013-05-17       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.